Demystified … Tissue microarray technology

Several “high throughput methods” have been introduced into research and routine laboratories during the past decade. Providing a new approach to the analysis of genomic alterations and RNA or protein expression patterns, these new techniques generate a plethora of new data in a relatively short time, and promise to deliver clues to the diagnosis and treatment of human cancer. Along with these revolutionary developments, new tools for the interpretation of these large sets of data became necessary and are now widely available. Tissue microarray (TMA) technology is one of these new tools. It is based on the idea of applying miniaturisation and a high throughput approach to the analysis of intact tissues. The potential and the scientific value of TMAs in modern research have been demonstrated in a logarithmically increasing number of studies. The spectrum for additional applications is widening rapidly, and comprises quality control in histotechnology, longterm tissue banking, and the continuing education of pathologists. This review covers the basic technical aspects of TMA production and discusses the current and potential future applications of TMA technology.

[1]  Dihua Yu,et al.  Early placenta insulin-like growth factor (pro-EPIL) is overexpressed and secreted by c-erbB-2-positive cells with high invasion potential. , 2002, Cancer Research.

[2]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[3]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[4]  H. Moch,et al.  Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. , 2001, Journal of the National Cancer Institute.

[5]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[6]  Ash A. Alizadeh,et al.  Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. , 2002, The American journal of pathology.

[7]  J. Chan,et al.  Reflections on the use of controls in immunohistochemistry and proposal for application of a multitissue spring-roll control block. , 2000, Annals of diagnostic pathology.

[8]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[10]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[11]  H. Moch,et al.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.

[12]  Martin Eisenacher,et al.  Cytogenetic Alterations and Cytokeratin Expression Patterns in Breast Cancer: Integrating a New Model of Breast Differentiation into Cytogenetic Pathways of Breast Carcinogenesis , 2002, Laboratory Investigation.

[13]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[14]  Thomas Rüdiger,et al.  Inter‐laboratory and inter‐observer reproducibility of immunohistochemical assessment of the Ki‐67 labelling index in a large multi‐centre trial , 2002, The Journal of pathology.

[15]  Holger Moch,et al.  Tissue Microarrays: What Will They Bring to Molecular and Anatomic Pathology? , 2001, Advances in anatomic pathology.

[16]  G. Sauter,et al.  Tissue microarrays for predictive molecular pathology , 2002, Journal of clinical pathology.

[17]  C Blake Gilks,et al.  Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. , 2002, American journal of clinical pathology.

[18]  R. Weinberg,et al.  Functional genomics and the breast cancer problem. , 2002, Cancer cell.

[19]  D. Slamon,et al.  Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. , 2001, The American journal of pathology.

[20]  H. Moch,et al.  Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer , 2002, Oncogene.

[21]  H. Battifora.  The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. , 1986, Laboratory investigation; a journal of technical methods and pathology.

[22]  Matt van de Rijn,et al.  Tissue Microarrays Are an Effective Quality Assurance Tool for Diagnostic Immunohistochemistry , 2002, Modern Pathology.

[23]  J. Peterse,et al.  Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. , 1992, Human pathology.

[24]  H. Müller-Hermelink,et al.  Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial. , 2002, American journal of clinical pathology.

[25]  H Buerger,et al.  Tissue microarrays: a new approach for quality control in immunohistochemistry , 2002, Journal of clinical pathology.

[26]  Ash A. Alizadeh,et al.  Towards a novel classification of human malignancies based on gene expression patterns , 2001, The Journal of pathology.

[27]  H. Moch,et al.  Tissue microarray (TMA) technology: miniaturized pathology archives for high‐throughput in situ studies , 2001, The Journal of pathology.

[28]  R. Tibshirani,et al.  Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome , 2022 .